Acquired transcriptional programming in functional and exhausted virus-specific CD8 T cells

Youngblood, Bena,b; Wherry, E. Johnc; Ahmed, Rafia,b

Current Opinion in HIV & AIDS:
doi: 10.1097/COH.0b013e32834ddcf2
SYSTEMS BIOLOGY IN UNDERSTANDING HIV PATHOGENESIS AND GUIDING VACCINE DEVELOPMENT: Edited by Rafick-Pierre Sekaly and Bali Pulendran
Abstract

Purpose of review: Failure to control viral infections such as HIV results in T-cell receptor (TCR) and inhibitory receptor driven exhaustion of antigen-specific T cells. Persistent signaling by these receptors during chronic viral infection sculpts the transcriptional regulatory programs of virus-specific T cells. The resulting gene expression profile is tailored to temper the potentially damaging effector functions of cytotoxic T cells and adapt them to an antigen-rich and inflammation-rich environment. Here we review recent studies investigating mechanisms of transcriptional regulation of effector, functional memory, and exhausted T-cell functions during acute versus chronic infections.

Recent findings: Patterns of gene expression in virus-specific CD8 T cells are a result of a combination of pro and inhibitory signals from antigen presentation (TCR-mediated) and co-inhibitory receptor ligation (PD-1, 2B4). Further, memory-specific transcriptional regulation of 2B4 expression and signaling impose a self-limiting secondary effector response to a prolonged viral infection. Additionally, differentiation of functional memory CD8 T cells is coupled with acquisition of a repressive epigenetic program for PD-1 expression. However, chronic infection provides a signal that blocks the acquisition of these epigenetic modifications reinforcing the suppression of cytotoxic lymphocyte (CTL) functions in exhausted cells.

Summary: Current findings suggest that the mechanism(s) that delineate functional memory versus exhaustion are coupled with acquisition of transcriptional programs at the effector stage of differentiation, reinforced by cessation or persistence of TCR signaling.

Author Information

aEmory Vaccine Center

bDepartment of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, USA

cDepartment of Microbiology and Institute for Immunology, University of Pennsylvania, Philadelphia, Pennsylvania, USA

Correspondence to Dr Ben Youngblood, Emory Vaccine Center, 954 Gatewood Road, Atlanta, GA 30329, USA. Tel: +1 404 727 4700; e-mail: byoungb@emory.edu

© 2012 Lippincott Williams & Wilkins, Inc.